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Understanding immune phenotypes 
in human gastric disease tissues by multiplexed 
immunohistochemistry
Le Ying1,3†, Feng Yan1,2†, Qiaohong Meng2, Xiangliang Yuan1, Liang Yu4, Bryan R. G. Williams5, David W. Chan6, 
Liyun Shi7, Yugang Tu8, Peihua Ni1, Xuefeng Wang9, Dakang Xu1,2,5* and Yiqun Hu1*
Abstract 
Background: Understanding immune phenotypes and human gastric disease in situ requires an approach that lev-
erages multiplexed immunohistochemistry (mIHC) with multispectral imaging to facilitate precise image analyses.
Methods: We developed a novel 4-color mIHC assay based on tyramide signal amplification that allowed us to reli-
ably interrogate immunologic checkpoints, including programmed death-ligand 1 (PD-L1), cytotoxic T cells  (CD8+T) 
and regulatory T cells (Foxp3), in formalin-fixed, paraffin-embedded tissues of various human gastric diseases. By 
observing cell phenotypes within the disease tissue microenvironment, we were able to determine specific co-local-
ized staining combinations and various measures of cell density.
Results: We found that PD-L1 was expressed in gastric ulcer and in tumor cells (TCs), as well as in tumor-infiltrating 
immune cells (TIICs), but not in normal gastric mucosa or other gastric intraepithelial neoplastic tissues. Furthermore, 
we found no significant reduction in  CD8+T cells, whereas the ratio of  CD8+T:Foxp3 cells and  CD8+T:PD-L1 cells was 
suppressed in tumor tissues and elevated in adjacent normal tissues. An unsupervised hierarchical analysis also identi-
fied correlations between  CD8+T and  Foxp3+ tumor-infiltrating lymphocyte (TIL) densities and average PD-L1 levels. 
Three main groups were identified based on the results of  CD8+T:PD-L1 ratios in gastric tumor tissues. Furthermore, 
integrating  CD8+T:Foxp3 ratios, which increased the complexity for immune phenotype status, revealed 6–7 clusters 
that enabled the separation of gastric cancer patients at the same clinical stage into different risk-group subsets.
Conclusions: Characterizing immune phenotypes in human gastric disease tissues via multiplexed immunohisto-
chemistry may help guide PD-L1 clinical therapy. Observing unique disease tissue microenvironments can improve 
our understanding of immune phenotypes and cell interactions within these microenvironments, providing the abil-
ity to predict safe responses to immunotherapies.
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Background
Host and tumor tissues undergo extensive immune inter-
actions, and the ability of the tumor to evade immune 
recognition often determines clinical outcomes. Immu-
notherapy has recently emerged as a novel approach in 
treating solid tumors. Tumor-infiltrating lymphocytes 
(TIL) play an essential role in mediating the response 
to immunotherapy and affect clinical outcomes in many 
cancer subtypes. The presence of TILs within the tumor 
microenvironment has been linked to better prognosis in 
gastric cancer [1]. “Immunologic checkpoints” expressed 
on cells in the tumor microenvironment or on the sur-
face of tumor cells (TCs) can promote immune escape by 
inducing apoptosis in immune effector cells. One such 
immune checkpoint is programmed cell death protein 1 
(PD-1). The binding of PD-1 to its ligand programmed 
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cell death 1 ligand 1 (PD-L1) leads to a blockade of 
kinases involved in T cell activation. PD-L1 expres-
sion on TCs is associated with worse prognosis in many 
malignancies [2]. Many recent studies have reported that 
the response to immunotherapy primarily depends on 
the expression of PD-L1 in the tumor microenvironment. 
These findings suggest that the response to anti-PD-1 
hinges on pre-existing anti-tumor immune response and 
that anti-PD-1 acts to free the CD8 T cells from inhibi-
tion to exert their anti-tumor activities [3]. Furthermore, 
naturally occurring TILs can be detected in various solid 
tumors, even in metastatic stages [4]. Immunosuppres-
sive mechanisms within the tumor microenvironment 
have been associated with the failure of TILs [5]. Bio-
markers of immune phenotypes are most commonly 
identified using immunohistochemistry (IHC). Studies 
using quantitative IHC have identified  CD8+ T cell infil-
tration as an important prognostic factor in predicting 
outcomes in patients with gastric cancer [6].  CD8+ T 
cells are regulated by regulatory T cells (Tregs). Among 
all Tregs, Foxp3-expressing Tregs are well known to play 
a critical role in tumor immune evasion [7], which has 
been reported in a wide array of human malignancies 
including our study in gastric cancer [7, 8]. Furthermore, 
upregulation of Tregs is associated with significantly 
reduced  CD8+ T cell infiltration of tumors and with 
worse outcomes for cancer patients [9]. However, the 
clinical implications of immunosuppressive processes 
related to immunologic checkpoints (PD-L1, CD8, and 
Foxp3) in tumors or immune cells in the tumor microen-
vironment remain controversial, and the potential use of 
these checkpoints as prognostic markers requires further 
study.
Tissue microarrays (TMAs) are commonly employed 
in clinical and basic-science research, it is a powerful 
tool for undertaking large-scale tissue-based biomarker 
studies [10] and has been widely used in many studies 
that involved in immune infiltrates studies [11, 12]. Tis-
sue sections from TMAs also offer the opportunity to 
understand a patient’s disease condition, to make bet-
ter prognostic evaluations and to select optimum treat-
ments. But tissues are often assessed primarily based 
on visual analysis of one or two molecules, image anal-
ysis is starting to address the variability of human sam-
ples. This is in contrast to measure characteristics such 
as parameters revealed through co-expression, spatial 
relationships, heterogeneity, and low abundance mol-
ecules. Those factors are understood to be critical to 
develop effective therapeutic strategies [13]. So far, TMA 
performance across multiple biomarkers has not been 
systematically explored. Here the multiplex immuno-
histochemistry (mIHC) was employed in our study for 
mapping the tumor microenvironment. This technology 
allows us to explore the relationship between various 
cell types in the peritumoral and intratumoral compart-
ments through more comprehensive and efficient analy-
sis of the tumor microenvironment. mIHC quantifies the 
change in expression or state of specific biomarkers and 
examines their impact on patient disease status for both 
mechanistic and diagnostic studies, potentially advancing 
our understanding of immune phenotypes and cell inter-
actions in the microenvironment while also providing 
better direct patient treatment based on individual tumor 
microenvironment responses to immunotherapy, offering 
improved response rates with gastric disease [14]. Here 
we developed a 4-color multispectral quantitative fluo-
rescent immunohistochemistry methods to detect CD8, 
Foxp3 and PD-L1 simultaneously.
Methods
Sample and tissue microarray preparation
Gastric cancer tissues were obtained from Shanghai 
Jiao Tong University, Ruijin Hospital. These tissues were 
formalin-fixed and paraffin-embedded for use. All of 
the protocols using human specimens were approved 
by Shanghai Jiao Tong University, and informed consent 
was obtained from all of the subjects. One TMA (TMA 
1) included 30 gastric cancer tissues from patients, but 7 
samples were excluded due to incompleteness. Another 
TMA (TMA 2) contained 30 various gastric disease sam-
ples (6 normal tissues, 9 gastric ulcer tissues, 1 gastric 
polyp tissue, 3 gastric intraepithelial neoplasia tissues, 
6 gastric carcinoma tissues and 6 normal adjacent tis-
sues), of which 2 normal tissues, 1 gastric ulcer tissue, 1 
gastric polyp tissue and 1 gastric carcinoma tissue were 
also excluded due to incompleteness. The remaining 49 
tissues were designated as Sample 1 to Sample 49 for fur-
ther analysis. Detailed information is shown in Additional 
file 1: Table S1. Two TMAs were made based on pathol-
ogy diagnosis of each tissues. The blocks were assembled 
and a surgical pathologist reviews the H&E slide for each 
case. The pathologist then circled the area of the block, 
localizing a representative tumor region from which a 
core will be extracted for our TMAs. Then we applied 
H&E staining on the two TMAs to validate pathology 
type of each tissue on each TMA, and the results of H&E 
staining was shown in Additional file  1: Figure S1. The 
core diameter on each TMA in this study is 2 mm, which 
is much larger than the normal TMA core (0.6 mm), to 
provide more representative tissues on TMA.
Immunohistochemistry
Gastric cancer paraffin blocks were processed into four-
micrometer-thick sections and mounted on slides for 
staining. Each slide contained 2 samples of the same tis-
sue. First, the slides were deparaffinized in xylene using 
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a graded ethanol series (75, 50, 25%). Antigen recovery 
was performed by microwaving the samples for 15  min 
in citrate buffer (pH 6.0), and the slides were cooled for 
30  min. Endogenous peroxidases were then blocked by 
treating the tissues with 3%  H2O2 for 10 min. Then, the 
tissues were incubated with blocking serum for 20 min at 
room temperature. Afterwards, the slides were incubated 
overnight with  CD8+T (1:500 dilution in SignalStain 
Antibody Diluent), PD-L1 (1:250 dilution in Signal-
Stain Antibody Diluent), and Foxp3 (1:350 dilution in 
SignalStain Antibody Diluent) primary antibodies (Cell 
Signaling, USA) at 4  °C and incubated with horseradish 
peroxidase (HRP) (Vectastain ABC kit, USA) for 30 min 
the next day. The slides were incubated with ABC rea-
gent (Vectastain ABC kit, USA) for another 30  min at 
room temperature, washed with TBST, and stained with 
3, 3′-diaminobenzidine (DAB). Finally, the slides were 
counterstained with hematoxylin and mounted with 
coverslips in DPX (Sigma, USA) for imaging. All stain-
ing preparations included a no primary antibody control, 
details are described by a previous study [15].
Multiplex immunohistochemistry
For mIHC staining, a PD-L1, Foxp3, and CD8a multiplex 
IHC antibody panel kit (Cell Signaling, USA) and Opal 
4-color fluorescent IHC kit (PerkinElmer, USA) were 
used [13]. First, the concentration and the order of the 
three antibodies were optimized, and the spectral library 
was built based on the single-stained slides. The slides 
were first deparaffined by xylene and ethanol (different 
concentrations) and antigen retrieval was performed 
by microwave. After incubating with 3%  H2O2 (freshly 
made) for 10 min, the tissues were blocked in blocking 
buffer for another 10  min at room temperature. Then 
the tissues were incubated by primary antibody (Cell 
signaling, USA), secondary-HRP (Cell signaling, USA) 
and Opal working solution (PerkinElmer, USA). The 
slides were mounted with ProLong Gold Antifade Rea-
gent with DAPI (Cell signaling, USA). All the slides were 
scanned using a Nikon C1 confocal microscope (Nikon, 
Japan), and images were analyzed by ImageJ software 
(National Institutes of Health, USA). The positive cell 
numbers of CD8 and Foxp3 were calculated by ImageJ 
software and the average intensity of PD-L1 was also 
analyzed by ImageJ software. The Analyze Particles tool 
in ImageJ was used to count the total number of posi-
tive CD8 and Foxp3 cells. Other details are described by 
a previous study [16]. The results were confirmed by two 
experienced pathologists blinded to the clinicopatho-
logical parameters (Additional file  1: Figure S2). The 
detailed protocol is described in the Additional file  1: 
Methods.
Statistical analysis
The statistical analysis was carried out using the Kruskal–
Wallis test for nonparametric analysis in GraphPad Prism 
(Version 5.0), and differences were considered statisti-
cally significant at p  <  0.05. Heatmaps and hierarchical 
clusters were generated in Rstudio (Version 3.2.0). Pear-
son correlation was performed by SPSS version 16.0 for 
Windows.
Results
Comparison of immunohistochemistry and mIHC 
to understand immune phenotypes in human gastric 
cancer
We hypothesized that analyzing cell–cell relationships 
via mIHC will provide a more complete view of tumor 
microenvironments than traditional IHC. To establish 
mIHC as a method for evaluating immune phenotypes in 
the microenvironments of human gastric disease, we first 
compared traditional IHC with more advanced 4-color 
mIHC. First, formalin-fixed, paraffin-embedded tissues 
from gastric cancer patients were stained by IHC. After 
optimization of the antibody dilution and antigen recov-
ery conditions,  CD8+T, Foxp3 and PD-L1 were detected 
in gastric cancer tissues.  CD8+T and Foxp3 were 
expressed in TILs, while PD-L1 was expressed in both 
tumors and TILs (Fig. 1a, b). PD-L1 showed membrane-
enriched expression (Fig.  1c). Then, mIHC was applied 
on the same paraffin tissues, and the mIHC experimen-
tal conditions were optimized individually with certain 
detection parameters and compared with IHC.  CD8+T, 
Foxp3 and PD-L1 expression patterns were very similar 
with the IHC results in the same tissue sections (Fig. 1d–
f). Clearer images of tumor microenvironments were 
observed using 4-color multispectral immunofluorescent 
staining. As shown in Fig. 2, CD8 was observed to express 
on the surface of lymphocytes (Fig.  2a–c) while Foxp3 
expressed in the nuclear of the lymphocytes (Fig. 2b–f). 
PD-L1 was observed in the membrane and/or cytoplasm 
of tumor and stromal cells (Fig. 2g–i). PD-L1 is a member 
of the B7 family of cell surface ligands that regulate T cell 
activation and immune responses [17]. The PD-L1 ligand 
binds the PD-1 transmembrane receptor and inhibits T 
cell activation. Thus, analyzing multiple cells markers 
 (CD8+T, Foxp3 and PD-L1) (Fig. 2j–l) allows us to assess 
spatial and interaction relationships, which provide valu-
able information for their relative function in this disease. 
To better understand the pathology type of the tissue, we 
applied H&E staining on the paraffin tissues to validate 
the pathology type of gastric cancer samples (Fig. 2m–o). 
Based on the results of H&E staining (Fig.  2m–o) and 
4-color mIHC staining (Fig. 2j–l), the gastric cancer tis-
sue in Fig.  2 is the typical representative sample that 
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showed CD8, Foxp3 and PD-L1 expressed in tumor-infil-
trated lymphoid tissues.
Differential expressions pattern of  CD8+T, Foxp3 and PD‑L1 
in gastric diseases
To assess differences in the expression of  CD8+T,  Foxp3+ 
and PD-L1, two TMA slides were used to compare the 
differences between gastric cancer tissues and other 
common gastric diseases, such as gastric ulcers. The two 
TMA slides were stained under the same experimental 
conditions after optimization as described above. There 
were totally 49 samples of different gastric diseases with 
28 gastric cancer tissues, 4 normal gastric tissues, 8 gas-
tric ulcer tissues, 3 gastric intraepithelial neoplasia tissues 
and 6 tumor normal adjacent tissues in two TMA slides 
(Additional file  1: Table S1). Six representative images 
are shown in Fig. 3. In the normal gastric mucosa tissue 
(Fig.  3a), gastric ulcer tissue (Fig.  3b), gastric intraepi-
thelial neoplasia tissue (Fig. 3c) and normal adjacent tis-
sue (Fig.  3d),  CD8+T cells displayed different patterns 
depending on the disease. However, different patterns of 
immune infiltration were observed in gastric tissues from 
diseases, including normal gastric mucosa, gastric ulcer, 
gastric intraepithelial neoplasia and gastric cancer. Even 
in gastric cancer, two distinct patterns of immune infil-
trate were observed in our cohort: patients with exten-
sive immune infiltrates, which here presented extensive 
PD-L1 and  Foxp3+ expression (Fig.  3e), and those with 
limited immune infiltrate, whose tissue presented little 
PD-L1 and limited Foxp3 expression (Fig. 3f ). This result 
was consistent with that of Wu et al., who reported that 
approximately 42.2% of gastric carcinoma tissues can be 
detected by PD-L1 [18].
CD8+T, Foxp3 and PD‑L1 expression correlated 
with immune phenotypes in different gastric diseases
To quantitatively compare the different levels of  CD8+T, 
Foxp3 and PD-L1 expression between various types of 
gastric disease and cancers, all the samples on the TMA 
slides were scanned using a Nikon confocal microscope. 
The numbers of  CD8+ T cells and  Foxp3+ cells per  mm2 
were analyzed and calculated in ImageJ, along with the 
average PD-L1 intensity. All images were also scored by 
two experienced pathologists, yielding similar results 
(Additional file 1: Figure S2). As summarized in Fig. 4, 
no differences were observed between different tis-
sues regarding the number of  CD8+ T cells. However, 
the number of Foxp3 cells was significantly (p  <  0.01) 
higher in gastric cancer tissues (319  Foxp3+ cells per 
 mm2) than in normal adjacent tissues (25  Foxp3+ cells 
per  mm2). PD-L1 expression in gastric cancer tissues 
(17.41 PD-L1 average intensity per  mm2) was also sig-
nificantly higher than in normal gastric mucosa tissues 
(0.34 PD-L1 average intensity per  mm2) and normal 
adjacent tissues (0 PD-L1 average intensity per  mm2). 
Interestingly, PD-L1 expression was also increased in 
gastric ulcer tissues (Fig. 4), possibly due to Helicobacter 
pylori infection [19].
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Fig. 1 Comparison between IHC staining and 4-color mIHC staining of paraffin-embedded gastric cancer tissue (× 10). a–c IHC staining of CD8 
(1:500), Foxp3 (1:350) and PD-L1 (1:250). d, e 4-color mIHC staining of CD8a (1:500), Foxp3 (1:350) and PD-L1 (1:250). DAPI was used to visualize 
nuclei (blue color), FITC corresponds to PD-L1 (green color), Cy3 represents Foxp3 (yellow color), and Cy5 indicates CD8 (red color)
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The ratios of  CD8+T:Foxp3+ and  CD8+T:PD‑L1 cells were 
suppressed in tumor tissues
Based on the above results,  CD8+T is insufficient for 
predicting the ability to generate TILs. However, when 
we evaluated the relative proportion of  CD8+T and 
 Foxp3+ cells, the ratio was highly significant (p  <  0.05) 
among different gastric tissues, and the normal adjacent 
tissues possessed a significantly higher ratio of  CD8+T 
10x   20x 40x
200 µm mµ05mµ001
200 µm
200 µm
200 µm
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Fig. 2 mIHC images with individual channels in gastric cancer tissues. a–c CD8 expression (red color) in gastric cancer tissues (a 10 × image; b 
× 20 image; c × 40 image). d–f Foxp3 expression (yellow color) in gastric cancer tissues (d × 10 image; e × 20 image; f × 40 image). g–i PD-L1 
expression (green color) in gastric cancer tissues (g × 10 image; h × 20 image; i × 40 image). j–l Merge pictures of mIHC images (j × 10 image; k 
× 20 image; l × 40 image). m–o H&E staining images (m × 10 image; n × 20 image; o × 40 image). DAPI was used to visualize nuclei (blue color), 
FITC was used to visualize PD-L1 (green color), Cy3 indicates Foxp3 (yellow color), and Cy5 corresponds to CD8 (red color)
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and  Foxp3+ cells compared with gastric cancer and gas-
tric ulcer tissues (Fig. 5a). When we calculated the ratio 
of  CD8+ and PD-L1+ cells, the ratios observed in nor-
mal adjacent tissues were also significantly higher than 
those in gastric cancer and normal gastric mucosa tissues 
(Fig.  5b), suggesting potential immunosuppressive roles 
for Foxp3 and PD-L1.
To dissect the immune phenotypes and cell inter-
actions among  CD8+T,  Foxp3+ and PD-L1 in the 
microenvironment, heatmap and clustering analy-
ses were performed to assess the potential correlation 
between different gastric diseases. First, we examined 
the 49 samples to see their clustering results based on 
the of  CD8+T, Foxp3 and PD-L1 expression. As shown in 
Fig. 5c, all the samples clustered into 3 groups: one group 
contained two special samples of gastric cancer (higher 
CD8 expression), another contained most of the gastric 
cancer tissues (higher Foxp3 and PD-L1 expression), and 
CD8
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Fig. 3 4-color mIHC images of different samples (× 20). a Normal gastric mucosa tissue (Sample 24). b Gastric ulcer tissue (Sample 30). c Gastric 
intraepithelial neoplasia tissue (Sample 38). d Normal adjacent tissue (Sample 44). e Gastric cancer tissue (Sample 43). f Gastric cancer tissue (Sam-
ple 47)
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the third group contained different types of gastric tis-
sues. The group containing most of the gastric cancer tis-
sues possessed higher PD-L1 and Foxp3 levels. However, 
PD-L1 was expressed partly in gastric cancer tissue based 
on the results of Fig. 5d (sample 9, gastric cancer tissue). 
Some gastric cancer also expressed lower PD-L1 (Fig. 5e, 
sample 12, gastric cancer tissue and Fig.  5f, sample 20, 
gastric cancer tissue).
Therefore, the ratio of CD8:Foxp3 and CD8:PD-L1 was 
used as a signature to determine the hierarchical cluster-
ing results of the 49 samples (Fig. 5h). All of the samples 
were divided into three main groups. One main group 
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contained most of the gastric cancer tissues and gastric 
ulcer tissues based on their low CD8/Foxp3 and CD8/
PD-L1 expression, as shown in Fig. 5d, e. Other normal 
tissues and gastric disease tissues, which exhibited rela-
tively high expression of CD8/Foxp3 and CD8/PD-L1, 
were clustered into another group (Fig.  5g, sample 24, 
normal gastric mucosa tissue), and two normal adjacent 
tissues comprised the third group.
CD8, Foxp3 and PD‑L1 signature in gastric cancer tissue
To dissect the immune phenotypes and cell interactions 
among  CD8+T,  Foxp3+ and PD-L1 in the microenvi-
ronment, we further aim to refine subgroups in gastric 
patients. The heatmap and clustering analyses were per-
formed to assess the potential correlation between 
different gastric diseases. However, we cannot distin-
guish each disease immune phenotype by single marker 
 CD8+T,  Foxp3+ and PD-L1 clustering analyses (Fig. 5c). 
But when using the ratio of CD8:Foxp3 and CD8:PD-L1 
for the hierarchical clustering, we were able to divide the 
samples into three main groups and correlated to the 
disease. One main group contained most of the gastric 
cancer tissues and gastric ulcer tissues based on their 
low CD8/Foxp3 and CD8/PD-L1 expression, as shown in 
Fig. 5h. Other normal tissues and gastric disease tissues, 
which exhibited relatively high expression of CD8/Foxp3 
and CD8/PD-L1, were clustered into another group. The 
hierarchical clustering was also supported by additional 
Pearson correlation analysis in gastric cancer tissues. As 
shown in Fig.  6a–c, the correlation coefficient between 
the expression of CD8 and Foxp3 in gastric cancer tissues 
was 0.479 (p < 0.01). Moreover, the expression of Foxp3 
was also high correlated with PD-L1 with the coefficient 
of 0.473 (p < 0.05). However, no significant relationship 
was found between the expression of CD8 and PD-L1 in 
gastric cancer tissues. Then we applied hierarchical clus-
tering analysis in gastric cancer tissues (Fig.  6d). Based 
on the ratio of CD8:PD-L1, gastric cancer tissues were 
divided into three groups. However, after adding the ratio 
of CD8/Foxp3 for the further clustering analysis, more 
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than 6–7 subtype gastric cancer immune phenotype 
formed, which indicated the complexity of classification. 
These more refined groups may help us to divide gastric 
cancer patients of the same clinical stage into different 
risk subgroups, which could potentially be useful for pre-
diction and treatment guidelines of PD-L1 therapy.
Discussion
We established a novel 4-color mIHC method that facili-
tates studying multiple parameters simultaneously in 
gastric disease tissues, which can illuminate important 
suppressive mechanisms within the tumor microenvi-
ronment [20]. This technology may help overcome the 
limitations of conventional single-color immunohisto-
chemistry approaches used to classify patients based on 
the degree of their CD3 and CD8 T cell infiltration [21]. 
Here, our data revealed that the interactions between dif-
ferent immune populations serve as a better predictor 
compared with CD8 T cell density alone. Furthermore, 
by integrating this tool with unsupervised hierarchi-
cal analysis, we are able to observe the correlation pat-
terns and signatures of CD8 and Foxp3 TIL densities and 
PD-L1 levels, which may indicate that PD-L1 regulates 
the immune response. This finding may be important 
in understanding the mechanisms of action of therapies 
and developing predictive biomarkers for more direct 
therapy.
Through the application of digital pathology tools for 
biomarker discovery and validation,  CD8+ T cell infil-
trates have been shown to have prognostic value in vari-
ous types of cancer. High densities of CD8 and PD-L1 
staining correlate with responses to anti-PD-1 immuno-
therapy agents in renal cell carcinoma (RCC), melanoma 
and non-small cell lung cancer (NSCLC) [22]. Patients 
with both high levels of T cell infiltrates and high PD-L1 
expression in their tumors may fail to respond to anti-
PD-L1 therapy. Complex tumor microenvironments are 
difficult to encapsulate with single markers such as CD8 
and PD-L1. Thus, utilizing multiparametric analyses of 
immune checkpoints, including PD-L1, CD8 and Foxp3, 
to study the interactions between cell types may provide 
a more comprehensive view of immune phenotypes and 
signatures in the tumor microenvironment, which may 
help develop predictions and accurately stratify patients 
compared with CD8 alone.
The link between PD-L1 expression and immuno-
therapeutic outcomes can vary, possibly due to differ-
ent IHC assays. Unresolved issues, including different 
staining protocols, different antibody protocols, and 
different scoring methods for identifying target cells 
as TCs, tumor-infiltrating immune cells (TIICs), etc., 
likely contribute to the unstable PD-L1 landscape. We 
used the E13LN clone from Cell Signaling Technologies, 
which demonstrates greater antibody sensitivity com-
pared with other PD-L1 antibodies. We also optimized 
the experimental conditions to compare traditional IHC 
and 4-color mIHC using the same antibodies. Auto-
matic identification of specific cells and tissue compart-
ment types using trainable feature recognition algorithms 
was also implemented for our pattern and morphology 
analysis.
Immune responsiveness to the presence of a tumor is 
dependent on the proximity lymphocytes to the tumor. 
Endogenous  CD8+ tumor-infiltrating T cells have been 
identified in a small series of patients with advanced gas-
tric cancer [23]. These naturally occurring  CD8+ TILs 
can specifically recognize autologous tumor-derived 
cells. However, in tumor regression during late-stage 
gastric cancers, TILs are rarely seen in the tumor micro-
environment, suggesting that TILs are more common 
in early-stage disease which we selected stage II cancer 
patients and that advanced gastrointestinal malignan-
cies are less immunogenic due to the selection pressure 
of some cancer cell during disease progression [24]. 
Multiple large studies have shown that increased PD-L1 
expression correlates with worse prognosis, highlight-
ing the prognostic power of PD-L1 expression in gastric 
cancers [25]. Elevated the expression of PD-L1 is asso-
ciated with advanced stage, more nodal metastases and 
worse outcomes [26]. The PD-L1 pathway has become an 
important target in cancer immunotherapy. However, the 
prognostic value of PD-L1 for gastric cancer still remains 
controversial due to the complexity of the tumor and 
immune cells interaction. For this propose, to compre-
hensive evaluation of PD-L1 expression, Foxp3 and  CD8+ 
T cells is necessary and superior to predicting these 
interactions.
Recent study showed that  molecular classification 
dividing gastric cancer into four subtypes: (1) tumors 
positive for Epstein–Barr virus, which display recur-
rent PIK3CA mutations, (2) extreme DNA hypermeth-
ylation, (3) amplification of  JAK2,  CD274  (PD-L1) 
and  PDCD1LG2  (PD-L2); (4) microsatellite unstable 
tumors (Microsatellite instability, MSI), which show 
elevated mutation rates, including mutations of genes 
encoding targetable oncogenic signalling proteins [27]. 
Those interesting data showed that PD-L1/2 expres-
sion was elevated in EBV-positive tumors by 9p ampli-
fications, which were enriched in the EBV subgroup 
(15% of tumors). These results may indicate that those 
molecular classification associated with immune phe-
notype (checkpoint), will be worth to follow up in the 
association between checkpoint and expression of EBV, 
phenotype of MSI in a much larger number of gastric 
cancer tissues and also relative survival data in our 
future study.
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The main aim of this study was to analyze the tumor 
microenvironment by analyzing 3 markers on 4-μm-thick 
gastric disease tissue sections. Overall, we found that 
the method was reproducible. Our data showed that 
PD-L1 was expressed in gastric ulcers, TCs and TIICs 
but not in normal gastric mucosa or other gastric 
intraepithelial neoplasia tissues. Furthermore, the ratios 
of  CD8+T:Foxp3 and  CD8+T:PD-L1 were suppressed 
in tumor tissues. Using the  CD8+T:PD-L1 ratio, we 
were able to divide the samples into three class groups, 
and further integrating the  CD8+T:Foxp3 ratio, which 
increased the complicity of immune phenotypes status, 
we defined 6–7 signatures and allowed the separation 
of gastric cancer patients at the same stage into differ-
ent risk-group subsets (Fig.  6). Thus, increasing tumor 
PD-L1 expression correlated with response rate in a 
recent PD-1 inhibitor (KEYNOTE-012) phase I clinical 
trial, which supported a trend toward improved overall 
response rate (ORR) and progression-free survival (PFS) 
[28]. However, a few cases with lower responses also had 
high levels PD-L1 expression, suggesting that using the 
 CD8+T:Foxp3 and  CD8+T:PD-L1 ratios to define 6–7 
clusters to separate gastric cancer patients into different 
risk subgroups may be useful for predicting and guiding 
PD-L1 therapy.
Conclusions
In conclusion, mIHC allows us to better understand 
immune phenotypes in human gastric disease tissues. 
Our sub-analysis indicated that the ratios of cytotoxic T 
cells to regulatory T cells  (CD8+T:Foxp3) and cytotoxic 
T cells to PD-L1  (CD8+T:PD-L1) tended to predict anti-
tumor interactions in the microenvironment, indicating 
that the combination of  CD8+T, Foxp3 and PD-L1 exhib-
its more predictive potential than PD-L1 expression or 
 CD8+ TIL density alone. These finding will help identify 
situations in which PD-L1 blockade therapy may be use-
ful for patients with gastric cancer.
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